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Leiomyoma of the uterus is a benign tumor of the smooth muscle. It is the most 
common pathologic abnormality of the female genital tract. It is found in 20–50% 
of women older than 30 years but is rare in children and post-menopausal women. 
It can present as an asymptomatic pelvic mass or as abnormal vaginal bleeding, 
or it may be associated with painful urinary symptoms, sexual dysfunction and 
dyspareunia, infertility, and recurrent pregnancy loss. The etiology of uterine fibroids 
is unclear. Diagnosis by clinical history and physical examination, pelvic examination, 
ultrasound pelvis and CT scan, and MRI are helpful. Management can be medical 
hormonal or non-hormonal, open surgical, endoscopic, or uterine artery embolization.
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Preface
This book introduces an important subject, and aims to explore one of the most
common pathologic abnormalities of the female genital tract: leiomyoma of the
uterus, which is a benign tumor of the smooth muscle.
The occurrence of uterine leiomyoma increases with age, is found in 20–50% of
women older than 30 years, but is rare in children and post-menopausal women.
Uterine leiomyoma results in masses associated with a variety of gynecologic prob-
lems, the most prominent of which are asymptomatic pelvic mass and abnormal 
vaginal bleeding.
The majority of women are asymptomatic, but may suffer pain and heavy vaginal 
bleeding, or have other urinary symptoms. Uterine fibroids can also cause sexual 
dysfunction and dyspareunia, infertility, and recurrent pregnancy loss.
The etiology of uterine fibroids is unclear, but may be a hormone-related or
estrogen-dependent disease. Risk factors include race, age, genetics, and high BMI 
(obesity), and may be related to diet especially eating meat.
Diagnosis by clinical history and physical examination, pelvic examination, ultra-
sound pelvis and CT scan, and MRI are helpful.
Major complications can occur if the uterine fibroids are caused by iron deficiency
due to heavy monthly blood loss, which can cause fatigue, and sometimes transfu-
sion is needed due to severe anemia.
Fibroids may or may not interfere with fertility and pregnancy. However, submuco-
sal fibroids could cause infertility or recurrent pregnancy loss.
Fibroids may also raise the risk of pregnancy complications, such as fetal growth
restriction, preterm delivery, and placental abruption. Red degeneration of fibroids
during pregnancy can cause severe abdominal pain.
Can fibroids be prevented? Researchers have admitted that little scientific evidence
is available on how to prevent fibroids. Uterine fibroids may be prevented, and only
a small percentage of these tumors require treatment.
Healthy lifestyle choices, such as maintaining a normal weight and eating fruits and 
vegetables, may be able to decrease the risk of having fibroids.
Research suggests that using hormonal contraceptives may be associated with a
lower risk of fibroids.
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Management can be medical hormonal or non-hormonal, open surgical, endoscopic, 
or uterine artery embolization.
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Uterine Fibroids: Clinical 
Presentation
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Abstract
The signs and symptoms of leiomyoma are varied. Most patients with uterine 
fibroids are asymptomatic and require no treatment. This is especially so in patients 
with small subserosal and intramural leiomyomas. Such patients may have the 
leiomyomas discovered incidentally during workup for other medical condition 
such as pregnancy. Some of them are also incidentally discovered in hysterec-
tomy specimens for other pelvic masses. The common symptoms associated with 
leiomyomas include menorrhagia, pelvic pain or pressure, and subfertility. These 
symptoms vary from one patient to another and do not necessarily correlate to the 
size of the fibroids. Abdomino-pelvic examination may be normal if the fibroids are 
small. However, findings of a suprapubic mass and tenderness are not an uncom-
mon finding for bigger myomas.
Keywords: leiomyoma, asymptomatic, menorrhagia, pelvic pain, pressure symptoms
1. Clinical presentation of uterine fibroids
Uterine fibroids present with a variety of signs and symptoms. The majority of 
women are asymptomatic, and the fibroid masses often remain undiagnosed [1]. 
Among such women, the myomas may be discovered during investigation for other 
conditions [2–4]. More than 50% of patients with uterine fibroids have no symp-
toms. This is common for small myomas especially when subserosal. For instance, 
a patient would be discovered to have fibroids during an antenatal ultrasound 
assessment of the foetus or during imaging for assessment of other pelvic patholo-
gies such as appendicitis or ovarian masses. Fibroids would also be discovered in 
hysterectomy specimens done for other gynaecological conditions such as cervical 
and ovarian malignancies.
Among symptomatic women, abnormal uterine bleeding is the commonest com-
plaint [1]. This could be described as heavy, prolonged, bleeding between menses or 
painful bleeding. The other symptoms associated with leiomyomas include pelvic 
pain, pelvic pressure and subfertility.
2. Abnormal uterine bleeding
Menorrhagia, defined as an increase in the amount of blood loss per month, 
is the most common symptom of uterine fibroids [1]. Majority of women with 
fibroids describe an increase in the amount of menstrual flow with some either 
needing to use more pads than before, using ‘heavier pads’ or even using both a 
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tampon and a pad simultaneously. Some report flooding whereby the bleeding 
flows beyond the containing pad/tampon. This kind of bleeding may cause anae-
mia, one of the commonest complications of menorrhagia.
The mechanism by which fibroids cause menorrhagia has not been clearly estab-
lished. However, a few theories have been fronted [4]. These include an increase in 
the endometrial surface area especially from fibroids with a submucosal component. 
Heavy menstrual flow may also result from increased vascularity of the uterus due 
the increased endothelial growth factors, principally VEGF [3, 5]. Other probable 
mechanisms include interference with normal uterine contractility and endometrial 
ulceration over the myomas [6]. Menorrhagia may also result from venous conges-
tion due to compression of venous plexus within the myometrium and endometrium 
with resultant endometrial venule ectasia leading to profuse bleeding.
Menorrhagia since menarche implies a possibility of other mechanisms of men-
orrhagia [7]. These patients should be evaluated for coagulopathies as up to 13% 
may have von Willebrand disease. Occurrence of myomas in such patients serves to 
worsen the already existing heavy uterine bleeding. These patients should be evalu-
ated and managed by a multidisciplinary team including physicians, haematologists 
and gynaecologists.
Other bleeding abnormalities commonly reported include prolonged bleeding, 
bleeding between menses, frequent periods and irregular and unpredictable periods 
[1]. Intermenstrual bleeding is more likely for cervical fibroids especially when 
close to the endo-cervical canal. Ulceration of fibroids with a submucosal compo-
nent may also cause intermenstrual bleeding.
3. Pelvic pain
This is a less common symptom than abnormal uterine bleeding, and patients 
rarely present with pain as the sole complaint [4, 6]. Intramural fibroids may pres-
ent with dysmenorrhea alongside the menorrhagia. However, the dysmenorrhea 
may not always be associated with menorrhagia. Degenerative changes, common in 
pregnancy, may also cause pelvic pain. This is usually managed conservatively by 
analgesics and rest. Dyspareunia is less common.
Some patients may present with chronic pelvic pain and dyspareunia [1].
Acute pain may result from torsion of a pedunculated myoma’s pedicle, incar-
ceration of a myoma within the pelvis or even cervical dilatation by a submucous 
myoma [4]. Cervical torsion may result in catastrophic intra-abdominal bleeding 
necessitating emergency laparotomy/laparoscopy.
4. Pressure-/bulk-related symptoms
Depending on the size and location, uterine fibroids may compress the urinary 
bladder or rectum [4, 6]. Compression of the urinary bladder may present with uri-
nary frequency, difficulty emptying the bladder and even acute urinary retention. 
When large, myomas may cause ureteric obstruction and hydronephrosis, which is 
more common on the right.
Fibroids can also place pressure on the rectum and cause constipation.
Patients may also present with feeling of an abdominal mass without any 
apparent menstrual disturbances or pain. Such patients may be suspected during 
examination for other conditions. Large fibroids may also cause compression of 
the inferior vena cava leading to possible deep venous thrombosis of the lower 
extremities.
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5. Reproductive challenges
Patients with fibroids may present with subfertility [6, 8]. As the occurrence 
of both uterine fibroids and subfertility increases with age, so does the risk of 
aneuploidy and pregnancy loss. Therefore, the actual impact of fibroids on fertility 
is difficult to ascertain. Submucosal and intramural fibroids distorting the uterine 
cavity compromise fertility. Depending on the number, size and location, fibroids 
may distort the overall uterine anatomy and compromise fertility. Removal of such 
fibroids may enhance fertility. Up to 60% of patients have been shown to conceive 
spontaneously upon myomectomy.
Fibroids may also increase the rates of first and second trimester miscarriages 
[9]. They have also been implicated as a cause of recurrent pregnancy loss.
6. Pregnancy-related complications
Fibroids may present with acute pain in pregnancy due to degenerative changes 
[6, 8]. They may also cause premature rupture of membranes, preterm labour, 
abruption placenta, malpresentations, foetal growth restriction and increased 
operative deliveries. Leiomyomas may also cause postpartum haemorrhage, 
retained placenta and even puerperal sepsis.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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Leiomyomas represent the most common type of benign tumors of the female 
genital tract. Assiduous preoperative imaging findings reflect proper therapeutic 
mapping. In cases of female patients of reproductive age, the ultimate goal remains 
the fertility preservation and the quality of life of the patient. According to recent 
bibliography, bizarre leiomyomas remain a controversial issue regarding the preop-
erative and postoperative therapeutic mapping. Giant cells with pleomorphic nuclei 
and little or no mitotic activity compose the microscopic analysis of such lesions. 
Multidisciplinary approach is mandatory in order to establish ultimate diagnosis 
and treatment. Bizarre leiomyomas still represent a gray scale among the whole 
scientific community.
Keywords: bizarre myomas, uterus, fertility preservation
1. Introduction
The incidence of uterine fibroid tumors increases as women grow older, and 
they may occur in more than 30% of women 40–60 years of age (Figure 1). Risk 
factors include null parity, obesity, family history, black race, and hypertension.
Many tumors are asymptomatic and may be diagnosed incidentally. Many stud-
ies have indicated the proper therapeutic mapping in cases of nulliparous young 
patients.
Therapeutic strategy is strongly accompanied with age and fertility capacity of 
the patient. In cases of degenerated uterine fibroids in nulliparous patients, laparo-
scopic approach represents the gold standard of surgical confrontation.
In reproductive age women, 15–30% of these tumors are responsible for men-
strual disorders, anemia due to perfuse uterine bleeding, pelvic pain, pregnancy 
loss, rarely preterm birth, and percentage of infertility [1].
In order to establish a proper diagnosis and treatment, especially in women of 
reproductive age, there is a classification of uterine fibroids [2].
Major categories consist of submucosal, intramural, subserosal, and others 
(cervical, parasitic) (Table 1).
Many factors affect the therapeutic mapping of uterine myomas. Age of the 
patient, gynecologic or obstetrical history, previous surgical procedures and fertil-
ity preservation.
Uterine fibroids consist of smooth muscular tissue with always the possibility of 
malignant transformation. Tumor size and anatomic location are strongly accompa-
nied with assiduous therapeutic strategy.
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patient, gynecologic or obstetrical history, previous surgical procedures and fertil-
ity preservation.
Uterine fibroids consist of smooth muscular tissue with always the possibility of 
malignant transformation. Tumor size and anatomic location are strongly accompa-
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Figure 2. 
Abdominal MRI with enlarged uterine fibroid depiction. Researchgate.net.
Figure 3. 
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Figure 2. 
Abdominal MRI with enlarged uterine fibroid depiction. Researchgate.net.
Figure 3. 
Uterine fibroid embolization. Interventionalnews.com.
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Transvaginal ultrasonography reflects the first preoperative procedure, depending 
on the physician’s experience and technical sufficiency of the ultrasound machine.
Imaging findings as areas of cystic degeneration, enlarged and asymmetric 
vascularization, papillary protrusions, and possibly increased tumor markers as 
Ca-125/Ca 15-3/Ca 19-9 reveal preoperative procedures of malignant metaplasia [3].
In such cases, abdominal MRI can, without a doubt, guide the preoperative 
management [4] (Figure 2).
In order to avoid diffuse menorrhagia and procedures of diffuse intravascular 
coagulation, an appropriate solution consists of uterine fibroid embolization [5]. 
With the use of colloid substances, we can lead to fibroid necrosis and cell apoptosis 
(Figure 3).
There are cases after fibroid surgical dissection and abdominal or vaginal 
hysterectomy where the histopathologic evaluation confirms bizarre myomas. The 
dilemma is controversial especially in cases of female patients of reproductive age. 
The ultimate goal remains fertility preservation of such patients.
2. Discussion
All mentioned scientific guidelines reflect the pathway from general depictions 
of uterine anatomy and physiology to specific fibroid pathology.
Many authors complete their monograph concerning uterine fibroids. They 
described several tumors with similar macroscopic view as uterine fibroid, but 
microscopically they include large multinucleated tumor cells.
After WHO (World Health Organization) classification bizarre leiomyomas 
presented as fibroids with giant cells with pleomorphic nuclei and little or no mitotic 
activity [6].
In many cases they represent a histologic gray zone concerning the therapeutic 
mapping in female patients of reproductive age.
Before final diagnosis is established, assiduous examination of the specimen is 
mandatory focusing on terms of atypia or necrosis (simple, moderate, or severe).
Along with genetic predisposition and ovarian hormone stimulation, many 
growth factors are identified.
Besides genetic predisposition and ovarian hormones that play a major role in 
tumor expansion, a large number of growth factors have also been identified which 
favor expansion.
These are insulin-like growth factor (IGF), epidermal growth factor (EGF) and 
platelet-derived growth factor (PDGF), transforming growth factor beta (TGF 
beta), and basic fibroblast growth factor (BFGF) [7]. These may have a role to play 
in tumor expansion.
The major differential dilemma remains the establishment of bizarre uterine 
myomas versus endometrial stromal sarcoma (ESS) (Figure 4).
The main characteristics of ESS consist of infiltrative myometrium growth and 
vascular invasion, presence of necrotic areas, and mitotic activity [8].
Due to infiltration of the myometrial basal membrane, surgical dissection after 
staging of the lesion represents the gold standard. Multidisciplinary approach is 
mandatory in order to establish proper postoperative treatment.
In cases of metastatic ESS, neoadjuvant therapy or series of radiotherapy  
will understage the tumor expansion and make the tumor staging surgically 
feasible.
On the other hand, patients with positive progesterone or estrogen recep-
tors (ER+, PR+), can be treated postoperatively with hormonal agents such as 
 progestogens [9].
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Ki-67 as exceptional biomarker is strongly accompanied with proliferative activ-
ity and presence of necrotic areas. Many conducted studies have adjusted Ki-6 and 
successful postoperative management.
In primary stages of the lesion, fertility preservation in female patients of 
reproductive age remains a controversial dilemma [10].
The impact of bizarre leiomyoma on fertility is not well known. Bizarre leio-
myoma consists of a rare entity composing pleomorphic or symplastic cells which 
require assiduous histopathologic evaluation.
If fertility preservation is not required, the standard surgical intervention for 
bizarre leiomyoma that shows a benign clinical course is a simple hysterectomy 
[11, 12].
Due to rare incidence of bizarre myomas, in cases of female patients of repro-
ductive age with ultimate scope the fertility preservation, simple myomectomy as 
the gold standard remains a controversial issue.
Etiology concerning this issue depends on the identification difficulty during 
myomectomy between specimen surgical borders and myometrium. After histo-
pathologic evaluation and not clear surgical margins, there is an increased incidence 
of tumor recurrence [13].
On the other hand, surgical treatment with dissection part of the associated 
myometrium, can lead in a future pregnancy, to spontaneously membrane rupture 
and episodes of preterm birth.
Precise scientific evaluation of current bibliography, focusing on optimal treat-
ment in patients of reproductive age, reveals a lack of scientific guidelines.
Figure 4. 
Endometrial stromal sarcoma. H&E stain. Wikipedia.
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The ultimate scope of the above presentation reflects the stimulus of completion 
and composition new conducted studies, which will guide assiduously and clear all 
controversial issues.
Bizarre uterine myomas, as rare entity, still represent a gray area among the 
whole scientific society.
3. Conclusion
Bizarre uterine fibroids represent a controversial scientific zone in the current 
bibliography. More studies must be conducted in order to establish proper diagnosis 
and treatment.
Multidisciplinary approach is mandatory in cases of patients of reproductive 
age. The ultimate goal remains in such cases, always fertility preservation.
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Different Surgical Techniques for 
Management of Leiomyoma
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Abstract
The objective is to review the methods of treatment for all cases diagnosed as 
leiomyoma at Tertiary Teaching Hospital. This is a retrospective study on the medi-
cal files of all cases diagnosed as leiomyoma at King Abdulaziz University Hospital. 
It is a teaching hospital with a capacity of 800 beds in total and 180 beds in the 
Department of Obstetrics and Gynecology. The study was approved by ethical 
hospital committee to be performed from July 2016 till September 2018. The total 
number of admitted cases of Leiomyoma, with a clinical diagnosis and confirmed 
postoperatively with a histological pathology, were 385. About 244 of Leiomyoma 
were managed with hysterectomy (63.4%). Open myomectomy was the method of 
choice to treat 141 cases, which contribute to (36.4%), a different technique used, 
Hysteroscopic, laparoscopic or open depending on the age of the patients, location, 
type of leiomyoma and fertility preservation. A number of cases treated with open 
surgery were 70 out of 141 (49.6%) and laparoscopic myomectomy were 51 out of 
141 (36.2%); only 20 cases had hysteroscopic resection of myoma (14.2%). Although 
hysterectomy is not an acceptable method of treatment for leiomyoma by many 
patients, still it is the most common surgical method for the treatment of leiomyoma.
Keywords: leiomyoma, myomectomy, hysterectomy
1. Introduction
Uterine fibroids are called uterine leiomyoma. It is one of the primary causes of 
morbidity in women of reproductive age [1].
It is of unknown aetiology. Several factors attribute to underlay the development 
and incidence of these common tumours. The fibroid is hormone-dependent, and it 
is known that it is a mono-cellar disease (formed from a single cell) [2].
Pathology uterine leiomyoma grossly appears as solid, white, well-circumscribed 
round, and not encapsulated and shows whorled appearance on the histological 
section. The size varies as small as microscopic to a large considerable size [3].
In 25–30% of females, fibroids are diagnosed mostly as asymptomatic [3, 4]. It is 
one of the primary causes of irregular vaginal bleeding, menorrhagia and metror-
rhagia, and it can cause infertility, repeated abortions and a variety of pain and 
pressure symptoms [1].
Hysterectomy and myomectomy have been the modality used for symptomatic 
fibroids. In recent years, medical treatment as well as laparoscopic and hystero-
scopic procedures contribute too many myoma and some other modalities.
Hysterectomy is the most frequent surgical procedure for management of 
leiomyomas, but the removal of leiomyoma alone is called myomectomy leaving the 
uterus in place; this is the second most common treatment for this condition.
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The dilemma of choosing the right procedure depends on several factors: the age 
of the patient, size of the tumour, and fertility preservation. Fibroid frequency is 
diagnosed and treated; there are uncertainties and controversies among clinicians 
and women regarding the best way to manage them [5].
Complications of leiomyoma depend on the location of the fibroids. They can be 
a cause of irregular bleedings or continuous bleedings for a long time, and can also 
cause pain or constant pain, dysuria, constipation, and chronic bladder and bowel 
spasms. Rarely, they can be a cause of peritonitis. Infertility and recurrent abortion 
can be one of the presentations [6].
Hysterectomy is not an acceptable method of treatment of leiomyoma by many 
patients. The objective is to review the methods of treatment for all the cases 
diagnosed as leiomyoma at the Tertiary Teaching Hospital.
2. Methods
2.1 Settings and design
This is a retrospective study, data collected from medical files of all cases diag-
nosed as leiomyoma at King Abdulaziz University Hospital. It is a teaching hospital 
with a capacity of 800 beds in total and 180 beds in the Department of Obstetrics 
and Gynecology. The study was approved by ethical hospital committee to be 
performed from July 2016 till September 2018.
2.2 Data collection
The source was the medical record file, including the clinical and pathological 
diagnosis of leiomyoma, the surgical techniques of management, which include 
hysterectomy, open myomectomy, laparoscopic, and hysteroscopic myomectomy 
performed at King Abdulaziz University Hospital (KAUH).
2.2.1 Inclusion criteria
All patients were admitted with a diagnosis of benign leiomyoma and managed 
at KAUH. Exclusion criteria cases were found to be malignant or transferred to 
another facility, or if we found their chart was incomplete they were excluded from 
the analysis.
2.2.2 Statistical analysis
The Statistical Package for the Social Sciences (PC SPSS) was used to analyse 
data using different methods of statistical analysis.
3. Results
The total number of admitted cases of leiomyoma, with a clinical diagnosis and 
confirmed postoperatively with a histological pathology, were 385.
About 244 of Leiomyoma were managed with hysterectomy (63.4%). 
Myomectomy was the method of choice to treat 141 cases which contribute 
to (36.4%), a different technique used, Hysteroscopic, laparoscopic or open 
depending on the age of the patients, location, type of Leiomyoma, and fertility 
preservation.
19
Different Surgical Techniques for Management of Leiomyoma
DOI: http://dx.doi.org/10.5772/intechopen.89348
A number of cases treated with open surgery were 70 out of 141 (49.6%), lapa-
roscopic myomectomy were 51 out of 141 (36.2%), and only 20 cases had hystero-
scopic resection of myoma (14.2%) (Tables 1 and 2).
4. Discussion
In our study, 63.4% of leiomyoma patients were treated with hysterectomy. 
There are many options for management of leiomyoma, which is increasing, so 
patients should be counselled about these options.
Not only medical and surgical managements are available, but also other modali-
ties such as endometrial ablation and uterine artery embolization are available 
(Figure 1). Choosing an appropriate management should be based on the evidence 
to support specific procedures and treatments.
Here I am only listing the option of medical treatments which can be offered 
to women who prefer to preserve their uterus, and if conservative management 
indicated: medication, such as gonadotropin-releasing hormone agonists and 
progesterone hormone therapy, and other therapies, such as the selective oestrogen 
receptor modulator (raloxifene) or non-steroidal anti-inflammatory drugs [7].
A combination of MRI and ultrasonography high-intensity sound waves on the 
tumour, inducing coagulation necrosis can be used. Uterine artery embolisation and 
Myolysis, or Myolysis and endometrial ablation may reduce the need for subsequent 
procedures in patients with persistent bleeding.
5. Surgery
Surgery is the removal of leiomyoma only or removal of the whole uterus; and 
this is needed if severe symptoms exist or if leiomyoma fails to respond to other 
modalities. If the myoma is very small or is not causing any symptoms, usually we 
do not require any treatment.
Guidelines of ACOG for the management of leiomyoma exist in the literature 
with the risks and benefits of each option.
One of the significant factors in choosing the method of treating myoma is not 
only the skill of the surgeon, but also the experience of the centre in different avail-
able techniques.
Procedure Number of cases Percentage
Myomectomy 141 36.6
Hysterectomy 244 63.4
Total number 385 100
Table 1. 
Total number of cases diagnosed as leiomyoma and method of treatment.
Myomectomy Number of cases Percentage
Open myomectomy 70 49.6
Laparoscopic myomectomy 51 36.2
Hydroscopic myomectomy 20 14.2
Table 2. 
Number and percentage of the technique used for myomectomy.
Leiomyoma
18
The dilemma of choosing the right procedure depends on several factors: the age 
of the patient, size of the tumour, and fertility preservation. Fibroid frequency is 
diagnosed and treated; there are uncertainties and controversies among clinicians 
and women regarding the best way to manage them [5].
Complications of leiomyoma depend on the location of the fibroids. They can be 
a cause of irregular bleedings or continuous bleedings for a long time, and can also 
cause pain or constant pain, dysuria, constipation, and chronic bladder and bowel 
spasms. Rarely, they can be a cause of peritonitis. Infertility and recurrent abortion 
can be one of the presentations [6].
Hysterectomy is not an acceptable method of treatment of leiomyoma by many 
patients. The objective is to review the methods of treatment for all the cases 
diagnosed as leiomyoma at the Tertiary Teaching Hospital.
2. Methods
2.1 Settings and design
This is a retrospective study, data collected from medical files of all cases diag-
nosed as leiomyoma at King Abdulaziz University Hospital. It is a teaching hospital 
with a capacity of 800 beds in total and 180 beds in the Department of Obstetrics 
and Gynecology. The study was approved by ethical hospital committee to be 
performed from July 2016 till September 2018.
2.2 Data collection
The source was the medical record file, including the clinical and pathological 
diagnosis of leiomyoma, the surgical techniques of management, which include 
hysterectomy, open myomectomy, laparoscopic, and hysteroscopic myomectomy 
performed at King Abdulaziz University Hospital (KAUH).
2.2.1 Inclusion criteria
All patients were admitted with a diagnosis of benign leiomyoma and managed 
at KAUH. Exclusion criteria cases were found to be malignant or transferred to 
another facility, or if we found their chart was incomplete they were excluded from 
the analysis.
2.2.2 Statistical analysis
The Statistical Package for the Social Sciences (PC SPSS) was used to analyse 
data using different methods of statistical analysis.
3. Results
The total number of admitted cases of leiomyoma, with a clinical diagnosis and 
confirmed postoperatively with a histological pathology, were 385.
About 244 of Leiomyoma were managed with hysterectomy (63.4%). 
Myomectomy was the method of choice to treat 141 cases which contribute 
to (36.4%), a different technique used, Hysteroscopic, laparoscopic or open 
depending on the age of the patients, location, type of Leiomyoma, and fertility 
preservation.
19
Different Surgical Techniques for Management of Leiomyoma
DOI: http://dx.doi.org/10.5772/intechopen.89348
A number of cases treated with open surgery were 70 out of 141 (49.6%), lapa-
roscopic myomectomy were 51 out of 141 (36.2%), and only 20 cases had hystero-
scopic resection of myoma (14.2%) (Tables 1 and 2).
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In our study, 63.4% of leiomyoma patients were treated with hysterectomy. 
There are many options for management of leiomyoma, which is increasing, so 
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Not only medical and surgical managements are available, but also other modali-
ties such as endometrial ablation and uterine artery embolization are available 
(Figure 1). Choosing an appropriate management should be based on the evidence 
to support specific procedures and treatments.
Here I am only listing the option of medical treatments which can be offered 
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receptor modulator (raloxifene) or non-steroidal anti-inflammatory drugs [7].
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procedures in patients with persistent bleeding.
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this is needed if severe symptoms exist or if leiomyoma fails to respond to other 
modalities. If the myoma is very small or is not causing any symptoms, usually we 
do not require any treatment.
Guidelines of ACOG for the management of leiomyoma exist in the literature 
with the risks and benefits of each option.
One of the significant factors in choosing the method of treating myoma is not 
only the skill of the surgeon, but also the experience of the centre in different avail-
able techniques.
Procedure Number of cases Percentage
Myomectomy 141 36.6
Hysterectomy 244 63.4
Total number 385 100
Table 1. 
Total number of cases diagnosed as leiomyoma and method of treatment.
Myomectomy Number of cases Percentage
Open myomectomy 70 49.6
Laparoscopic myomectomy 51 36.2
Hydroscopic myomectomy 20 14.2
Table 2. 
Number and percentage of the technique used for myomectomy.
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Hysterectomy can be done in different ways, vaginal or abdominal; depending 
on the technique used, the procedure can be carried out using either general or 
regional (a spinal-epidural) anaesthesia [6].
In many prospective studies, there was an effort taken to reduce the frequency 
of abdominal hysterectomy, and conclude that all patients should be counselled in 
detail about the alternatives to hysterectomy so that they can share the decisions [8].
Vaginal hysterectomy versus abdominal hysterectomy; in a nine RCTs, 762 
women [3, 7]. It was found that the surgical approach to hysterectomy, the abdomi-
nal has more complications than other modalities; so the decision should be dis-
cussed with the patient.
6. Myomectomy
Myomectomy is considered as an alternative to hysterectomy for the treatment 
of leiomyoma, especially in patients who need to preserve their fertility.
Figure 1. 
Scheme of management of leiomyoma.
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Open myomectomy is useful in cases with multiple myomas, more than five and 
larger than 10 cm especially if deeply located.
Preoperative evaluation of the size and number of myomas is mandatory to 
reduce intraoperative and postoperative complications [9].
Up to 33% of women who have undergone this surgery will need a repeat proce-
dure because of recurrence of fibroids [10].
Laparoscopic myomectomy cases may become difficult if bleeding occurs. It 
might need more time and longer operative time and may require for morcellation 
and extensive laparoscopic suturing [11].
Gynecologists need to improve their laparoscopic skills. Laparoscopic 
Myomectomy was associated with rapid recovery less blood and minimal postop-
erative pain, and fewer overall complications, but longer operating times, when 
compared with open myomectomy for patients with fibroids [12].
Major complications, recurrence, and pregnancy were similar between treat-
ments. Depending on the personal experience and available equipment, the gynae-
cologist has a choice of several alternative procedures [13, 14].
In addition, one prospective randomised study [15] has provided good-quality 
evidence that surgical therapy (hysteroscopic myomectomy) yields higher preg-
nancy rates than alternative treatments in women with submucous myoma [16].
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Abstract
The hysteroscopic myomectomy is a very important application of the gynecologic
endoscopy, as it allows minimal invasive removal of the type 0, 1, and 2 fibroids with
minimal damage to the uterine wall. In the last decade, new developments of this
method allowed an even less invasive approach, with possibility of ambulatory proce-
dure. We discuss the importance of these new developments, based very much on the
pseudocapsule of the myoma, and analyze the literature data regarding the outcome.
The cold loop resection is a technique that could be used in type 1 and type 2 myomas,
with less complications and limitations than the classical electrical resectoscope. Another
development, more useful for type 0 and 1 myoma, is the hysteroscopic morcellator,
similar to the laparoscopic one, but providing a faster and safer procedure. We also
update the complications of hysteroscopic myomectomy and their management,
including long-term and obstetrical complications related to hysteroscopic myomec-
tomy. In conclusion, new developments and studies show that hysteroscopic myomec-
tomy has become a valid endoscopic technique ready to be used by many specialists.
Keywords: hysteroscopy, myomectomy, morcellator, cold loop resection,
complications
1. Introduction
Since 1976, the fibroids were accessible to hysteroscopic approaches as a conser-
vative treatment, especially for type 0 and type 1 of the European Society of
Gynaecological Endoscopy (ESGE) classification [1]. But the instruments needed an
approach requiring anesthesia and dilatation, exposing to numerous complications,
especially when using monopolar electric energy. Further developments, like
miniaturization of resectoscopes or the large introduction of bipolar energy, have
opened new and more accessible approaches with more and more specialists using
the hysteroscopic techniques and with lesser and lesser complications.
The recent years have brought a revolution in operative hysteroscopy, and
myoma treatment benefitted as well as other intrauterine pathologies. We will try to
point some of these developments and their applications in fibroid treatment.
2. Limits for office hysteroscopic myomectomy
The myomas are fibrotic tumors of the myometrium, with an incidence varying
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Abstract
The hysteroscopic myomectomy is a very important application of the gynecologic
endoscopy, as it allows minimal invasive removal of the type 0, 1, and 2 fibroids with
minimal damage to the uterine wall. In the last decade, new developments of this
method allowed an even less invasive approach, with possibility of ambulatory proce-
dure. We discuss the importance of these new developments, based very much on the
pseudocapsule of the myoma, and analyze the literature data regarding the outcome.
The cold loop resection is a technique that could be used in type 1 and type 2 myomas,
with less complications and limitations than the classical electrical resectoscope. Another
development, more useful for type 0 and 1 myoma, is the hysteroscopic morcellator,
similar to the laparoscopic one, but providing a faster and safer procedure. We also
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1. Introduction
Since 1976, the fibroids were accessible to hysteroscopic approaches as a conser-
vative treatment, especially for type 0 and type 1 of the European Society of
Gynaecological Endoscopy (ESGE) classification [1]. But the instruments needed an
approach requiring anesthesia and dilatation, exposing to numerous complications,
especially when using monopolar electric energy. Further developments, like
miniaturization of resectoscopes or the large introduction of bipolar energy, have
opened new and more accessible approaches with more and more specialists using
the hysteroscopic techniques and with lesser and lesser complications.
The recent years have brought a revolution in operative hysteroscopy, and
myoma treatment benefitted as well as other intrauterine pathologies. We will try to
point some of these developments and their applications in fibroid treatment.
2. Limits for office hysteroscopic myomectomy
The myomas are fibrotic tumors of the myometrium, with an incidence varying
a lot in function of different factors (age, race, family background, etc.). Their
23
particular structure has an outside pseudocapsule, which makes the myomectomy
through enucleation a rather simple technique in laparoscopy. For the fibroids
protruding into the uterine cavity (except the complete intracavitary type 0 ones),
although the capsule exists, the classical approach involved a slicing technique
which could impair also the surrounding myometrium, which is something not to
be desired especially in young patients that want to retain a good reproductive
prognostic.
The introduction of bipolar smaller resectoscopes allowed a more targeted tech-
nique. The new resectoscopes have an outer diameter of 7 mm, and this allows
minimal dilatation and anesthesia. Another possibility is the bipolar probe which
allows myolysis and separation from the pseudocapsule.
The use of the pseudocapsule has several advantages:
• The myoma can “move” in between the myometrial fibers, allowing its
persistence during uterine contractions. During the intervention, this
constitutes a cleavage plan that allows enucleation.
• Once disrupted, this pseudocapsule does not “protect” the myoma, and uterine
contractions expel the tumor toward the cavity. This principle was described
by as the auto-expulsion of the myoma—defined as the Office Preparation of
Partially Intramural Uterine Myoma (OPPIUM) by Bettocchi et al. [2], which
leaves the intramural part of the fibroid untreated in the first step. After the
next menstrual cycle, the protrusion allows the hysteroscopist to resect the rest
of the tumor.
This latest element is recommended in tumors exceeding 1.5 cm and with a large
implantation (type 1 or type 2). Although it generally requires a two-step interven-
tion, it offers security and facilitates the favorable final result.
Other limits to office hysteroscopic are [3]:
• Patient’s sensitivity to pain, which may require some form of paracervical
anesthesia and/or preoperative analgesic and antispasmodic drugs.
• The type of fibroid. Beside the cited ESGE classification, another classification
is the STEP-W, which was proposed for submucous myomas by Lasmar et al.
[4] and takes into account:
◦ Size—largest diameter of the nodule in cm (scored as 0 if <2 cm, 1 if
2–5 cm, and 2 if >5 cm).
◦ Topography in the uterine cavity (inferior part, 0; middle uterus, 1; and
upper part, 2).
◦ Extension of the base of the fibroid and proportion in which it covers the
corresponding uterine wall (scored as 0 if <1/3, 1 if 1/3–2/3, and 2 if >2/3).
◦ Penetration in the uterine wall—corresponding to the ESGE classification
(0, 1, or 2 type scored as such)
◦ Attachment of the fibroid to the lateral wall—if present add 1 point.
• The final score of STEP-W suggests the complexity of the case: if 0–4, easy
to perform hysteroscopic myomectomy; 5–6, complex procedure, possible
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two-step approach; and 7–9, difficult case, and the specialist should consider
alternatives to hysteroscopy.
If the myoma remains enucleated and free in the uterine cavity, there are
authors that advocate leaving it for spontaneous expulsion, in the Haimovich series
(after laser myomectomy) the median duration to expulsion being 68 days, with
no complication [5].
An important help for better assessing the pseudocapsule could be brought by
computer-aided imaging. A recent study of Török et al. [6] showed a very good
accuracy, of more than 86%, using fully convolutional neural networking and high-
resolution endoscopic image, which is promising for faster and safer future resections.
3. Assisting hysteroscopic myomectomy: preparation and safety
The hysteroscopic myomectomy is a method depending highly on several
factors, some related to the patient (tumor size and number, consistency, position)
and some to the equipment and experience of the gynecologist.
So, it is important that the preparation and safety are tackled with care.
One of the preparatory methods is the pre-treatment of fibroids. Several
strategies have been proposed, and here we will discuss especially the new ones:
a. Ulipristal acetate, an orally active selective progesterone receptor modulator,
could act through different mechanisms on myoma cells, inducing apoptosis,
changing the expression of pro-angiogenic proteins, and reducing the
production of collagen tissue. All these actions are obtained without
significantly diminishing the estrogen level, unlike other therapies (i.e.,
GnRH agonists). According to a systematic review by Ferrero et al. [7], there
are advantages and disadvantages in prescribing this treatment before
hysteroscopic myomectomy. The favorable effects are the amenorrhea and
diminished size of the fibroid, which would facilitate the resection. On the
other hand, the endometrium appears to increase, which could create
difficulties for visualization. Another mentioned change under medical pre-
treatment of myomas is the “myoma migration” which means that the
position and the type of fibroids could change after therapy and therefore
change the approach of the surgeon, from hysteroscopy to laparoscopy and
vice versa. As mentioned, this effect was also noted in the ulipristal-treated
group [8] as well as in those treated by GnRH analog or embolization [9].
b. Regarding the effect of GnRH analog, the effects on the facility and duration of
the hysteroscopic procedure is uncertain. As mentioned above, and in other
studies [10], most of the time, for type 2 myomas, the difference was not
significant in favor of the pre-treated group, but most of the series in literature
are rather small. As for other types of myomas, as no important volume
decrease was found, it should be emphasized that the only major advantage of
the pre-treatment is reducing or stopping the associated hemorrhage.
c. For the safety increase of the procedure, the use of ultrasound vaginal scan
has been shown to be of the greatest value. This allows estimation of the
operating time; for example, in a study by Isono et al. [11], using the cubic
value for the average diameter of the myoma was useful both in estimating
the total weight of the tumor and the operating time, with differences from
those with diameter of 1–2, 2–3, or >3 cm). During the procedure, the
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ultrasound scan has been proposed by Korkmazer et al. [12], for assessing the
limits of the remaining myometrial tissue after resection of type 1 and
especially type 2 myomas.
d. The 5 mm limit for safety from the serosa is the most accepted one for a safe
procedure diminishing the risk of perforation [13]. Although this was
considered a proven fact, new researches underline that the moment of
assessing could influence this parameter. The limited use of electric energy,
accompanied by squeezing the myoma from its pseudocapsule by hydro-
pressure fluctuation, and other pharmacological means could, according to
Casadio et al. [14], allow myomectomies of tumors with <5 mm security
margin.
4. Cold loop resection: principles and limits
With this procedure, the slicing done by electrical energy is replaced by a
mechanical dislocation assisted by the “natural” myometrial reaction to uterine
distension that helps push the tumor toward the uterine cavity.
This technique, first described by Mazzon in 1995, had overcome the limits of
classical slicing technique. It has several advantages, as described byMazzon et al. [15]:
• Less uterine perforations, as the mechanical energy allows the myometrial
tissue to contract.
• Sparing the myometrial fibers diminishes the hemorrhage associated, as it
allows the natural hemostasis done by myometrial contraction and avoids
damaging tortuous vessels in the deep myometrium.
• Diminishing vascular injuries also decrease the risk of distension media
intravasation.
• The intramural component of the myoma loses its importance and allows
smaller myoma-serosa interface than the 5 mm limit.
• The postoperative occurrence of intrauterine adhesions, a common
complication of large hysteroscopic myomectomies, is also lower after cold
loop technique.
The retrospective study of Mazzon [16] of 1244 cases showed a 87% of one step
myomectomy in general, and 82% for type 2 myoma. Other series also allowed large
myomas of >3 cm to be resected in one step by this technique, with an operating
time of 10–58 min [17].
In conclusion, the cold loop method offers advantages compared to the classical
electrical resectoscope one, and although it requires getting used to the use of
mechanical dissection of the tumor from its pseudocapsule, with appropriate force
and angle of insertion of the loop, it could have important benefit especially for
large and intramural fibroids—type 1 and 2.
5. Myomectomy using hysteroscopic morcellation
The morcellation of fibroids is a technique involving mechanical cutting of small
slices of tumor, accompanied by powerful suction of the fragments. The sectional
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mechanical effect is done, similar to laparoscopic morcellator, by rotation of an
inner tube into an outer tube at high speed. The advantages of the technique, as
mentioned in a large multicentric study coordinated by Scheiber et al. [18], are:
• A high efficacy, of 87% for fibroids and 99% for polyps
• The accessibility of the procedure, with similar results in ambulatory and
clinical settings
• The high satisfaction of operators, up to 95%
• Low complication rate, as no repeated insertion is needed as in resectoscopic
technique
A systematic review done by Vitale et al. [19] confirms the feasibility of the
different morcellators in practice, especially for type 0 and 1 myomas, while type 2
myomas are more difficult, with multistep procedures, as for classical resectoscopic
method. The diminished operating time, with an average of 22 min for over 280
patients in the included articles, is also an advantage.
An observation made by the authors of the cited review is that, due to the
aspiration system of tissues, a larger quantity of fluid is needed. If, in classical
resectoscopic myomectomy, the limit of 1000–1500 ml deficit should not be passed,
in morcellating technique, even at 2500 ml deficit there was no side effect men-
tioned. Nevertheless, the mean deficit was much lower, around 760 ml.
Another recent prospective study of Maheux-Lacroix et al. [20] analyzed the
follow-up for post-hysteroscopic morcellation patients for an average of 32 months
and found a 12% rate of hysterectomies and 27% of additional surgery overall. The
most significant factor for this outcome was the size of the myoma >5 cm, with
odds ratio (OR) of 2.9.
There is a tendency of reducing the size of the morcellator; the new equipment
with a diameter of 19 Fr (6.5 mm) allows minimal dilation and ambulatory pro-
cedures. Although this latest instrument is more suitable for polyps, Bigatti et al.
[21] describes a case with type 2 fibroid resected with this shaver.
6. Postoperative follow-up and complications
6.1 Postoperative follow-up
The immediate postoperative care for patients having undergone hysteroscopic
myomectomy includes surveillance of symptoms such as cramping, light bleeding,
and vaginal discomfort.
The drugs of choice for postoperative pain control are usually acetaminophen or
nonsteroidal anti-inflammatories. After discharge, patients are advised to use an
anti-inflammatory medication such as ibuprofen, which should provide adequate
pain control. Severe pain that does not respond to such medication can be a sign of a
more serious complication and should be promptly evaluated.
Postoperative surveillance is further dependent upon the course of the proce-
dure. If an imbalance of fluid was noted, then the patient should be monitored for
signs and symptoms of fluid overload and hyponatremia: bradycardia, hyperten-
sion, nausea, vomiting, seizures, pulmonary edema, or cardiovascular
abnormalities.
Routine activities are generally resumed within 24 h, and patients should follow
standard postoperative instructions for gynecologic procedures.
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Patients should be informed about further vaginal bleeding, which is anticipated
for 1 week after the surgery. The duration of bleeding may vary from a few days
to 2 weeks, and the flow usually is very light.
A follow-up visit should be scheduled to take place 4–6 weeks postoperatively,
when subsequent complications might be diagnosed and the pathology results
reviewed and discussed with the patient, especially since cases of unexpected uter-
ine malignancy in women undergoing hysteroscopic myomectomy were reported,
with an incidence of 0.86% [22].
6.2 Complications
Operative hysteroscopy is generally considered a safe and minimally invasive
procedure used for the treatment of uterine leiomyoma. Knowledge of early and
late adverse events, alongside preventative measures, is crucial for the safety and
quality of hysteroscopic surgery [23].
Studies regarding hysteroscopic myomectomy procedures report a complication
rate of 0.8–2.6% [24, 25].
A retrospective study regarding the follow-up of 235 women with submucous
fibroids at outpatient hysteroscopy who underwent a hysteroscopic transcervical
resection reports a complication rate of 2.6%, and the rate is lower for procedures
involving single versus multiple fibroids (1.4 vs. 6.7%) [24].
Among the gynecological procedures performed by hysteroscopy, myomectomy
imposes a lower risk for complications: adhesiolysis carries the highest risk of
complications (4.5%), followed by endometrial resection (0.8%), myomectomy
(0.8%), and polypectomy (0.4%), as shown by a prospective study of 2515 opera-
tive hysteroscopies [25].
The most common complications of hysteroscopic myomectomy can be divided
into early complications, such as uterine perforation, fluid overload, heavy bleed-
ing, infection, and late complications and suboptimal outcomes, such as incomplete
resection and intrauterine adhesions [23].
One of the most frequent complications of operative hysteroscopy is uterine
perforation, with an incidence of 0.12–3% [24–26]. The incidence increases in the
presence of risk factors for traumatic entry: menopausal status, cervical stenosis,
retroversion, and nulliparity. Signs and symptoms of uterine perforation include a
sudden increase in fluid deficit and loss of adequate intracavitary distention, which
generally results in loss cavitary distention, leading to termination of the procedure.
Nevertheless, it can result in bleeding and potentially significant injury to sur-
rounding organs, depending mainly on the type of instrument used.
If the perforation was caused by a blunt instrument during dilation of the cervix,
it can be managed conservatively if major bleeding is not suspected. In these cases
of suspected uterine perforation without hemodynamic instability and suspicion of
damage to major vessels, postoperative monitoring of red blood cell count is essen-
tial, and a single dose of prophylactic antibiotic may be considered [23].
Damage by electrosurgical electrodes may lead to more serious injuries [27]. In
this case, if a thermal or mechanical injury to surrounding viscera is suspected, a
diagnostic laparoscopy is necessary.
In the long term, uterine perforation is a potential cause of uterine rupture in
pregnancy which should not be neglected [28].
The incidence of fluid overload during operative hysteroscopy ranges between
1.6 and 2.5%, making excess fluid absorption one of the most common complica-
tions associated with hysteroscopic procedures [29].
The term “operative hysteroscopy intravascular absorption syndrome”
(OHIA) was introduced, regarding the excessive fluid overload caused by
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intravasation of distension media [23, 30], which further leads to hyponatremia
and volume overload [3] and, in severe cases, metabolic acidosis, pulmonary
and cerebral edema, and severe OHIA being associated with a mortality of
25% [30].
Continuous fluid monitoring, as well as thoughtful consideration of the disten-
tion media used, is an essential measure in preventing fluid overload. Isotonic
media and bipolar equipment are preferred in order to reduce the risk of
hyponatremia and its consequences [23]. Recent guidelines by the British Society of
Gynaecological Endoscopy (BSGE) and the European Society of Gynaecological
Endoscopy on fluid management in operative hysteroscopy recommend an upper
threshold of 2500 ml for isotonic media and for of 1000 ml hypotonic fluids, in
healthy women [31]. For patients with comorbidities or at an advanced age, lower
thresholds are recommended: fluid deficit levels of 750 ml for hypotonic solutions
and 1500 ml for isotonic solutions [31].
Heavy bleeding is uncommon after operative hysteroscopy but might occur due
to mechanical trauma to the endometrium and/or myometrial vessels. Management
options include intracervical injection of a prostaglandin F2α analog, resulting in
uterine contraction with subsequent decrease in uterine bleeding or an intracavitary
placement of a Foley catheter with a 30-ml balloon providing counterpressure. The
balloon can be deflated, and the Foley removed after the bleeding has subsided for
4 hours. In rare cases, the bleeding may persist and require uterine arterial emboli-
zation or hysterectomy [23].
The incidence of infection following operative hysteroscopy varies between 0.01
[5] and 1.42% [32]. Prevention of infection may be possible by reducing the dura-
tion of the intervention. Currently, there is no established role for prophylactic
antibiotic use.
Attention should be given to the possibility of postoperative uterine adhesion
formation, especially in patients with a desire for future fertility. This complication
is more likely to occur when lesions on opposing uterine walls have been resected so
that the surfaces are juxtaposed after the procedure is completed. In these instances,
estrogen therapy could be utilized immediately postoperatively, causing a rapid
development of the endometrium. Another method attempted in the past was the
placement of an intrauterine Foley catheter to prevent the contact between the
opposing surfaces. Performing a hysteroscopy 6 weeks after surgery can be helpful
both for diagnosis and for treatment by blunt dissection of adhesions with the tip of
the hysteroscope [33].
Although rare, cases with abnormal placentation following hysteroscopic resec-
tion of myomas have also been reported. In 2013, Mathiesen et al. have reported the
first case of placenta increta (associated with placenta previa) in a pregnancy after
hysteroscopic myomectomy, concluding that patients with a history of hystero-
scopic myomectomy are at an increased risk for abnormal placentation [34]. Tanaka
et al. have reported in 2016 a case of placenta accreta without placenta previa
during a pregnancy subsequent to hysteroscopic myomectomy, which was obtained
with cryopreserved embryo transfer, which has been reported as an independent
risk factor for placenta accreta. The authors suggest that any patient with previous
hysteroscopic myomectomy should be considered to be at high risk for placenta
accreta, even if she does not develop placenta previa [35].
Regarding the efficacity of hysteroscopic treatment of myomas, studies show a
high success rate of hysteroscopic resection of uterine leiomyoma, of >94% [24],
depending on prognostic factors such as the size, location, and number of myomas.
The incidence of incomplete resection rates ranges from 5 to 20.5% [23, 36].
Reinterventions are usually performed, but may not always be necessary [23].
Comorbid conditions such as adenomyosis or dysfunctional uterine bleeding can
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result in persistent menorrhagia that may indicate a subsequent hysterectomy for
definitive treatment.
7. Conclusion
The hysteroscopic myomectomy has benefitted from the technical develop-
ments in equipment, and things appear to continue. Both new instrumentations and
a more physiological approach to the myoma enucleation could be increasing the
safety and the efficacy of this type of procedures.
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Abstract
Uterine fibroids or leiomyomas are benign, hormone-dependent smooth muscle 
cell tumors that can be associated with menorrhagia, anemia, pelvic pain, urinary 
and/or intestinal symptoms, and dyspareunia. Traditionally, the mainstay of 
treatment has been surgical, consisting of hysterectomy or myomectomy. However, 
uterine artery embolization has become an increasingly utilized, minimally inva-
sive treatment modality that can be offered as either sole therapy or as a staged, 
pre-operative measure to hysterectomy. A thorough knowledge of pelvic vascular 
anatomy and facility with specific embolotherapeutic techniques are required for 
safe and effective fibroid embolization.
Keywords: uterine artery embolization, uterine fibroid, embolic agent, menorrhagia, 
internal iliac artery
1. Introduction
Uterine fibroids (UF), or leiomyomas, are benign tumors arising from uterine 
smooth muscle. UF are common with reported lifetime prevalence rates approach-
ing 70% in Caucasian women and over 80% in African American women [1]. 
Symptomatic fibroids—estimated to comprise less than 50% of all UF—are most 
commonly associated with menorrhagia and subsequent anemia in women of 
reproductive age [2]. As UF grow in volume, symptoms related to bulk effects, 
including constipation, bladder dysfunction, tenesmus, and chronic back and 
pelvic pain become problematic and may warrant intervention.
Controversy exists regarding the effect of UF on fertility. Several systematic 
reviews have reported evidence of increased rates of spontaneous abortion and 
decreased fertility [3, 4]. Because these reviews included numerous studies drawn 
from populations of women seeking reproductive assistance, the results presented 
may not be generalizable to all reproductive-aged women. A systematic review of 
studies drawn from general obstetric populations found no relation between risk of 
spontaneous abortion and presence of UF [5].
The traditional approach to UF management has been surgical. Hysterectomy 
remains the predominant intervention, with myomectomy an option for women 
desiring to maximize fertility. Uterine artery embolization (UAE) is a minimally 
invasive and uterine preserving procedure that has become an attractive therapeu-
tic alternative over the last 20 years. Its efficacy and acceptable safety profile have 
helped establish the technique as a viable approach with minimal complications for 
women interested in retaining their uterus and avoiding invasive surgery [6]. The 
procedure involves percutaneous transarterial catheterization and embolization 
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2. Risk factors and pathophysiology
The exact etiology of UF remains unclear. Several factors are thought to contrib-
ute to the overall risk of developing UF, including black race, nulliparity, advanced 
age prior to menopause, obesity, and hypertension [7, 8]. Menarche before age 10 
and oral contraceptive use are also associated with increased risk [7, 9]. Bleeding 
and bulk symptoms associated with UF tend to ameliorate with menopause, sug-
gesting that the persistence of UF depends on hormonal status [2]. There also exists 
a hereditary component, with first degree relatives of women affected by UF having 
a 2.5 fold higher risk of developing UF [10]. Recurrent chromosomal alterations 
and genetic mutations are found in a fraction of all UF [11, 12]. Protective factors 
include multiparity, a well-balanced diet, and progestin-only injectable contracep-
tion [7, 9, 13].
UF are classified based on their extent and location within the uterus. Broadly, 
submucosal fibroids are found immediately below the endometrium; subserosal 
fibroids beneath the serosal uterine surface; intramural fibroids within the myo-
metrium; and pedunculated fibroids are suspended from the uterus by a stalk and 
may project into the peritoneal or uterine cavities. The International Federation of 
Obstetrics and Gynecology classification system describes UF localization on an 
eight-point scale with lower values denoting closer fibroid proximity to the endo-
metrium and uterine cavity [14].
Submucosal fibroids carry an additional risk of endocavitary expulsion post-
UAE [15]. Those with larger endometrial interface to maximum dimension ratio 
are even more likely to be completely or partially expelled into the uterine cavity. In 
general, larger masses are associated with higher complications rates, although the 
majority of endocavitary masses pass with few symptoms [15]. For women whose 
UF fit the above profile and wish to undergo UAE, explaining the risk and symp-
tomatology of fibroid expulsion is essential to minimize post-procedural distress 
and ensure prompt engagement with their physician should expulsion manifest.
3. Imaging
Identification of UF is often incidental to pelvic examination or pelvic imaging. 
In patients with suggestive symptoms, trans-abdominal or trans-vaginal ultrasound 
is initially performed [16]. Color flow Doppler interrogation of the mass can help 
delineate the degree of vascularity of the UF. B-mode imaging can help delineate the 
location, depth, extent, and configuration of the UF. Further details of the uterine 
mass, including presence of potential malignancy, vascularization patterns and 
anastomoses, and the risk for passage of the infarcted mass, can be captured using 
contrast-enhanced MRI. Importantly, pre-procedural MRI provides a baseline mea-
sure of perfusion that can be tracked to measure the degree of infarction post-UAE 
[17–19]. It is important to note that imaging ought to be performed in coordination 
with a thorough gynecologic evaluation and examination including endometrial 
biopsy to rule out other etiologies. A multidisciplinary approach to patient care in 
close collaboration with colleagues in gynecology can lead to excellent outcomes [20].
4. Indications and patient selection
Asymptomatic UF discovered incidentally can generally be managed non-oper-
atively under the supervision of a gynecologist. Women experiencing symptomatic 




options available to them. Numerous guidelines have described the best practices 
for UAE based on reported clinical evidence [21]. A consistent picture regarding 
the ideal candidate for UAE is presented across guidelines: a patient with symptom-
atic fibroids (bleeding, pain, mass effects) who wishes to avoid invasive surgery. 
Frequently reported absolute contraindications include viable pregnancy and active 
infection [21]. Commonly cited relative contraindications include immunocom-
promised status, hostile anatomy for endovascular intervention, renal impairment, 
contrast allergy, or previous uterine surgery.
Variability exists among guidelines regarding relative contraindications. Several 
guidelines recommend considering some UF as unsuitable for UAE based on the 
relative position of the mass in the uterus; with pedunculated, submucosal and 
subserosal fibroids variably suggested as being unsuitable for UAE [21–24]. Other 
guidelines make no such recommendations regarding UF positioning, leaving the 
anatomical suitability of a patient for UAE at the discretion of the treating physician 
[21, 25]. Patient desire to retain fertility is similarly divisive. Some guidelines cite a 
small reported advantage in fertility outcomes of women treated with myomectomy 
compared to UAE as rationale for recommending against UAE in women desiring 
future fertility [26, 27]. Other studies have demonstrated similar rates of fertility 
and complications associated with pregnancy in women treated with UAE when 
compared with the general population [28, 29]. Definitive evidence regarding the 
effects of UAE on fertility remains outstanding. It is our practice to recommend 
against UAE in patients wishing to maintain fertility [20].
Larger UF measuring greater than 10 cm or large uteruses greater than 24 weeks 
were once considered contraindications to UAE based on case reports detailing poor 
outcomes in women bearing these features [30]. Continued research and experi-
ence, however, has demonstrated the safety and efficacy of UAE for treatment of 
large UF and large uteruses [31, 32]. We currently do not recommend against UAE 
based on UF or uterine size alone [20].
The determination of the best treatment approach for a given patient with UF 
should begin with a consultation that covers a complete history and physical, a 
review of OB/GYN examination and assessment, the type and degree of symptoms, 
and a review of any available imaging. Ascertaining the patient’s desire for future 
fertility and uterus preservation are important considerations in guiding interven-
tion selection. In cases where UAE is indicated, explaining the risks associated with 
the procedure, including bleeding, infection, access site complications, possible 
negative effects on fertility and the potential need for surgical reintervention and 
hysterectomy, offers the patient a full account on which to base their decision.
Though rare, other indications for UAE include abnormal placental development, 
such as placenta previa, accreta, increta, and percreta. These conditions are commonly 
treated by emergency hysterectomy and carry a high risk of intrapartum hemorrhage, 
respiratory distress syndromes, kidney failure, and death. Hybrid prophylactic bilateral 
UAE and caesarian section has been described to increase the safety of fetus delivery 
and to minimize the risk of intrapartum hemorrhage from placental detachment [33]. 
In a hybrid operating room, bilateral uterine arteries are first cannulated and the infant 
is delivered. While the umbilical cord is clamped and the vaginal cavity is packed 
with the placenta in situ, both uterine arteries are embolized. In a series of 12 patients 
who underwent UAE-assisted cesarean section, 10 patients retained their uterus and 
2 underwent hysterectomy [33]. There was no mortality, minimal blood loss and no 
post-operative infection. In these cases, the risk of low dose radiation to the fetus is 
considered negligible compared with baseline risks for all developmental abnormalities 
[34]. UAE may fall under the purview of multiple specialties, and a collaborative effort 
among gynecologists, interventional radiologists, and vascular surgeons is necessary to 
expand the availability of UAE and/or other surgical measures to more women [20].
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5. Vascular anatomy of the female pelvis
It is vital to delineate the normal vascular anatomy and its variations for prevention 
of non-target embolization. In its most common configuration (77%), the internal 
iliac artery (IIA) bifurcates into two main stems, one anterior and one posterior. Other 
modes of IIA division include three-stem in 14%, four- or more-stem in 3%, and 
one main stem in 4% of cases. The anterior division branches include the obturator, 
umbilical/superior vesical, uterine, vaginal, inferior vesical, middle hemorrhoidal, 
inferior gluteal, and internal pudendal arteries. The posterior trunk gives rise to the 
iliolumbar, the lateral sacral, and the superior gluteal arteries. The superior gluteal 
artery is invariably the terminal branch. While the iliac bifurcation and the origin 
of the IIA is best visualized under contralateral anterior oblique projection, we have 
found ipsilateral anterior oblique projections to best demonstrate the origin and course 
of the uterine artery once the IIA has been adequately accessed and catheterized [35].
The diameter of the uterine artery varies from 2 to 5 mm and is usually larg-
est during pregnancy and immediately after childbirth. It has a U-shaped course. 
It initially courses caudally against the pelvic wall, then horizontally across the 
ureter, and at last cranially along the uterus. Its three major terminal branches are 
the artery of uterine fundus, medial tubal branch, and medial ovarian artery. It 
is important to be aware of the medial ovarian branch coursing along the utero-
ovarian ligament, as it anastomoses with a branch originating from the ovarian 
artery. The medial ovarian branch provides the total ovarian supply in 4% of the 
cases. Uterine artery branches are extensively anastomosed with the contralateral 
uterine artery, as well as with the ipsilateral ovarian and the inferior epigastric 
arteries. While the uterine artery provides most of the arterial supply of the uterus, 
the ovarian artery and the artery of the round ligament also contribute [36].
UF are not fed by a specific branch, but by a peri-myomatous plexus. In the 
presence of fibroids, the branches of the uterine artery are distorted and larger in 
caliber [16]. The superficial surface of UF are usually enveloped in a dense perifi-
broid arterial plexus whereas the core of the mass remains relatively hypovascular 
[16, 37]. The ovarian arteries contribute to UF arterial supply in 5–10% of the cases, 
especially in patients who have disturbed arterial networks secondary to prior pel-
vic surgery, tubal or ovarian pathologies or a large fundal fibroid. Round ligament 
arteries and lumbar arteries are rare sources of UF perfusion. Left–right uterine 
artery anastomoses are identified in roughly 10% of patients and ovarian-uterine 
artery anastomoses in 10–30% [16]. On the contrary, pedunculated fibroids are 
generally perfused by a solitary artery coursing through the fibrotic stalk. A pro-
posed risk of necrosis and deterioration of the stalk with liberation of the mass into 
the peritoneal cavity has been used as a justification for classifying pedunculated 
fibroids as a relative contraindication to UAE [38]. Nevertheless, contrast-enhanced 
magnetic resonance imaging (MRI) of pedunculated fibroids treated with UAE 
found intact vascularization of the peduncle stalk with successful infarction of the 
mass and no complications related to UF location [38]. Other work has suggested 
that pedunculated fibroids are less likely to be completely infarcted following UAE 
although no clinical outcome data were reported [39]. The suitability of UAE in the 
treatment of pedunculated fibroids remains an outstanding issue. We currently do 
not recommend against UAE in patients with pedunculated UF configurations.
6. Choice of embolic agent
An array of embolic particles has been developed and employed in clinical prac-




particles (nsPVA; Merit Medical, South Jordan UT). nsPVA are non-uniform in size 
and shape and are, therefore, dependent on thrombus formation to produce complete 
occlusion of the uterine artery lumen [40]. nsPVA also tends to occlude microcath-
eters and complicate delivery. MRI assessment of UF treated with UAE using nsPVA 
frequently showed recanalization of infarcted UF in a majority of women 6 months 
post-intervention, highlighting the need for newer embolic agents suited for UAE 
[41]. Thus, spherical polyvinyl alcohol (sPVA) particles were developed to address the 
size and shape variation of nsPVA; however, in practice, sPVA particles (Contour SE 
microspheres; Boston Scientific) produced inferior improvements in symptoms and 
smaller reductions in UF size post-UAE [42].
Gelatin sponge—a biodegradable agent derived from purified gelatin—has been 
used as an embolic agent in cases of hemorrhage, and has been employed success-
fully as an embolic agent in UAE [43]. Preparing the gelatin sponge agent from the 
stock material requires hand manipulation, which produces inconsistencies in size 
and shape thereby limiting quantifiable comparisons with other more consistently 
prepared embolic agents.
Particle size influences the degree of distal embolization and potential for 
non-target embolization [31]. The observed caliber of perifibroid arterial vessels is 
between 500 and 800 μm, which justifies the typical use of calibrated particles in 
the 500–700 or 700–900 μm range [44]. Employing smaller sized particles is associ-
ated with an increased risk of uterine necrosis and should therefore be avoided [45].
Tris-acryl gelatin microspheres (TAGM; Embospheres; Merritt Medical, South 
Jordan, Utah) are calibrated microspheres that come in sizes ranging from 40 to 
1200 μm. When used for UAE, TAGM sized 500–700 μm are typically employed 
and have demonstrated distal penetration into the UF vasculature with minimal 
proximal aggregation that is observed with nsPVA [40].
A new entrant in the embolic material space is F-coated Hydrogel Microspheres 
Embozene; CeloNova BioScience, Newnan, Georgia. These microspheres are 
comprised of a hydrogel core of polymethylmethacrylate encased in a malleable 
polyphosphazene shell. These particles are biostable and are available in a range of 
sizes from 40 to 1300 μm [40]. Early experience with these agents has demonstrated 
safety and efficacy in the treatment of UF [46].
With the exception of greater symptomatic improvement with TAGM use as 
compared to sPVA, outcomes and complications of the other embolic agents gener-
ally suggests no clear evidence of superiority of TAGM [40, 42]. There is a need for 
better powered studies to differentiate among the different embolic agents.
7. Technical procedure
UAE is generally performed in a hybrid operating suite or catheterization suite 
under general or moderate sedation anesthesia. The latter requires ability and 
willingness of the patient to cooperate with positional and ventilatory instructions 
intraoperatively to maximize imaging quality as well as the accuracy of micro-
catheterization and embolic agent delivery. In the absence of contraindications, 
chemical and mechanical deep vein thrombosis prophylaxis via prophylactic dose of 
enoxaparin, graded stockings, and sequential compressive devices is administered 
before induction of anesthesia.
The single femoral artery approach is adequate to access both the ipsilateral and 
contralateral uterine arteries. The micropuncture technique is used for femoral 
arterial access. In young healthy women, clinically significant vasospasm is a serious 
consideration and must be monitored regularly. We suggest immediate availability 
of vasodilatory agents for intrarterial administration if necessary. In order to avoid 
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arterial vasospasm, some interventionalists recommend ceasing GnRH analog 
treatment several weeks before treatment [20, 35].
Over a guidewire, a 5 F multisidehole catheter of choice is advanced into 
the midabdominal aorta. Flush aortography is performed looking for pelvic 
hypervascular neoplastic changes and dilation and tortuosity of the feeding UAs. 
Contralateral obliquity of the image intensifier facilitates visualization of the ipsi-
lateral iliac bifurcation. Under roadmap guidance, selective catheterization of the 
IIA is performed using an angled guidewire and a 5 F C2 catheter (Merit Medical, 
South Jordan UT). Selective angiogram of the IIA in ipsilateral obliquity commonly 
facilitates visualization of the UA ostium. This image is then roadmapped. A coaxial 
microcatheter-based platform (Direxion; Boston Scientific, Marlborough, MA) is 
then developed over an 0.014 steerable guidewire, the tip of which can be curved 
manually before intrarterial insertion to help facilitate engagement of the target 
vessel ostium and to help overcome extreme arterial tortuosity.
Superselective microcatheterization of the UA is then performed with advance-
ment of the catheter to the proximal-most branches of the uterine artery feeding 
the fibroid. Use of power injector for angiography is essential as manual contrast 
infusion through the small caliber, high resistance microcatheter platform can 
be difficult and lead to suboptimal imaging. Once the satisfactory positioning of 
microcatheter tip is confirmed on angiography, the system is copiously flushed with 
heparinized saline in preparation for the delivery of embolic agent [20].
The embolic agent is delivered in bursts through the microcatheter under 
fluoroscopic guidance with intermittent heparin saline flush. Extreme care is taken 
to avoid reflux of the embolic agent particularly toward the end of each session 
when greater resistance to flow is encountered. The system is then gently flushed 
with heparinized saline to irrigate out the residual embolic content within the 
microcatheter. This must be performed under fluoroscopic visualization to prevent 
nontarget embolization. Adequate devascularization of the UF from the accessed 
side is then confirmed on completion angiography of the ipsilateral IIA through the 
5 F C2 catheter after removing the microcatheter coaxial platform.
Up-and-over technique is used to similarly catheterize the contralateral UA and 
deliver embolic agent as described previously. Completion aortoiliac angiogram 
is performed to ensure adequate UF devascularization and to rule out nontarget 
embolization.
Alternative techniques have been reported. Bilateral femoral puncture with 
sequential UA catheterization and simultaneous embolization is associated with 
reduced fluoroscopy time, reduced procedure time, and no added complication 
risk when compared to unilateral femoral puncture [47]. Transradial access (TRA) 
has been employed successfully in percutaneous coronary interventions for years, 
and studies exploring the suitability of TRA for UAE have been promising [48, 49]. 
In those patients with sufficient collateral perfusion of the hand and suitable radial 
artery anatomy, TRA may have 100% technical success rate with no immediate 
complications [49]. Patients usually enjoy fewer restrictions in positioning and 
movement following the procedure and report satisfaction with the freedom 
offered by TRA.
8. Outcomes and complications
Accumulated evidence over decades has supported the use of UAE in the 
treatment of uterine masses in a safe and efficacious manner. Expected outcomes 
following UAE include a 50–60% reduction in UF size, an 88–92% reduction in bulk 




and a patient satisfaction rate of 80–90% [25, 26]. Reduction in UF size can be 
visualized within weeks of UAE and continues for 3–12 months following the 
procedure. Histopathological analysis of successfully infarcted UF is characterized 
by coagulative or hyaline necrosis [50]. The degree of UF infarction as captured 
by contrast enhanced MRI 24–72 hours post-UAE has been reported to predict 
the magnitude and durability of symptomatic improvement as well as risk for 
reintervention [51]. Women exhibiting 100% infarction on post-operative imaging 
enjoyed a 0% reintervention rate after 24 months, whereas women with almost 
complete (90–99%) or partial (<90%) infarction experienced reintervention rates 
of 20 and 50%, respectively.
Interventional success is generally defined as reducing blood flow through the 
UA to near stasis and causing complete infarction of the UF [6]. Gradual revas-
cularization of the myometrium occurs in the weeks following UAE while the UF 
ideally remains infarcted and regresses. Failure rates range from 20 to 28%, most 
likely due to incomplete embolization of the UF vasculature, recanalization of the 
UF vasculature, or the persistence and engorgement of collaterals feeding the UF 
post-UAE [6, 52]. Identification of collateral blood supply to the UF, either before 
UAE using an aortogram or MRI, or peri-procedurally using cone-beam CT angiog-
raphy, will inform the embolization procedure and ensure all vessels supplying the 
UF are targeted [6, 53]. In cases where the ovarian artery is found to supply the UF, 
either independently or via a utero-ovarian anastomosis, embolization of the ovarian 
artery is required to ensure complete infarction of the UF. Despite the risk of ovarian 
compromise following ovarian artery embolization in this scenario, reports studying 
the effects of ovarian artery embolization in conjunction with UAE have found no 
evidence of menopause precipitation, nor worsening of menopausal symptoms [52]. 
This is in contrast to prior work that reported roughly 40% of women over the age of 
45 experienced ovarian failure following UAE without ovarian artery embolization 
[54]. Among women under the age of 45, no cases of ovarian failure were observed. 
These observations suggest that, should UAE negatively affect the ovarian capacity, 
the extent of ovarian function compromise is related to the patient’s age at the time 
of the procedure.
Post-embolization syndrome, involving pelvic pain, low-grade fever, nausea, 
loss of appetite, and malaise, is almost inevitable following UAE. The treatment is 
supportive, consisting of antipyretic, fluids, analgesia, and anti-inflammatory med-
ication. Over 90% of women undergoing UAE report pain following the procedure, 
making pain management an important consideration in caring for these patients 
[55]. Admitting patients for a 24-hour observation period allows for pain manage-
ment under the direct care of their physician. [20] Several approaches have been 
reported that aim to reduce post-procedural pain and opioid use in these patients. 
Peri-procedural superior hypogastric nerve block using a 0.75% ropivacaine solu-
tion is effective in minimizing post-procedural pain and significantly reduces total 
opioid usage [55]. A single pre-procedural dose of intravenous dexamethasone can 
also improve patient pain scores and reduce markers of inflammation. However, 
the total opioid use in these patients has been found not to be significantly different 
from those not receiving pre-procedural dexamethasone [56].
The most commonly reported long-term complication associated with UAE is 
permanent amenorrhea. Women over 45 years of age are reported more likely to 
experience permanent amenorrhea following UAE (20–40%) than women under 45 
(0–3%) [25]. Transient amenorrhea following UAE is often observed and may be a 
consequence of non-target ovarian artery embolization although this is not consid-
ered a major complication. Other observed complications include persistent vaginal 
discharge, transcervical expulsion of infarcted tissue, prolonged and intractable 
pain, and infection [25]. Very rare cases of deaths have been reported following 
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ered a major complication. Other observed complications include persistent vaginal 
discharge, transcervical expulsion of infarcted tissue, prolonged and intractable 
pain, and infection [25]. Very rare cases of deaths have been reported following 
Leiomyoma
42
UAE as a result of pulmonary embolization, sepsis, and embolization of occult 
leiomyosarcoma [31].
Reintervention is indicated, should UF related symptoms return secondary to 
resumed growth of the primary UF or growth of a new UF. Reported reinterven-
tion rates range from 14 to 35% [26, 57]. Reinterventions may include repeat UAE, 
hysterectomy, or myomectomy. Patients undergoing UAE should be counseled 
regarding the risks of reintervention. Fostering long-term relationships with 
patients undergoing UAE allows for tracking of outcomes and early intervention 
should symptoms re-emerge [25].
While several guidelines cite preservation of fertility as a relative contrain-
dication to UAE, uncertainty remains regarding fertility outcomes following the 
procedure [21]. Published case series following pregnancies in women attempting to 
conceive following UAE found an overall pregnancy rate of ~30% [58]. As com-
pared to the general obstetric population, women treated with UAE have similar 
or increased rates of obstetric complications, with specifically increased rates of 
miscarriage and cesarean section deliveries [58, 59]. Notably in the majority of these 
studies, women with UF treated by UAE were older than the general obstetric popu-
lation and carried additional risk factors, which may explain some of the observed 
increases in complication rates. For women with complex UF pathology who desire 
to retain their uterus and avoid invasive surgery, UAE may be presented as an option 
that preserves some chance of conception in the future.
9. Comparison with hysterectomy and myomectomy
The traditional approach to the treatment of symptomatic fibroids has been 
surgical, with hysterectomy being the most common [60]. Complete removal of the 
uterus is a definitive treatment for UF that precludes recurrence and may be a suit-
able recommendation for women who have completed child bearing. Though rates 
of hysterectomy are decreasing, the lifetime prevalence among U.S women as of 
2012 was 45%, with nearly one-third of all hysterectomies performed as treatment 
of UF [60]. While laparoscopic hysterectomy has become more commonplace, open 
hysterectomies remain most frequently employed.
Myomectomy is a uterine sparing surgical intervention best suited to the 
removal of one to three fibroids in an anatomically accessible location [31]. Like 
hysterectomy, myomectomy may be done laparoscopic or open, with the laparo-
scopic approach associated with fewer complications and quicker recovery [61]. For 
women with submucosal fibroids projecting into the intrauterine cavity, hystero-
scopic myomectomy is a suitable option that is associated with quick recovery and 
return to daily living [2].
Laparoscopic management of UF, either by hysterectomy or myomectomy that 
employs power morcellation for specimen removal, has been associated with a risk 
of dissemination of occult sarcoma [31]. Histopathological analysis of hysterectomy 
specimens shows a 0.4% rate of unsuspected malignancy in uteruses treated for UF 
[62]. Under these circumstances, patients should be informed of the risk of occult 
malignancy dissemination.
Growing clinical experience and promise of UAE in the treatment of UF 
motivated the design and execution of several randomized clinical trials (RCTs) 
comparing medium- and long-term outcomes and patient satisfaction with UAE 
compared with surgical interventions. The embolization versus hysterectomy 
(EMMY) trial recruited women with symptomatic UF and assigned them 1:1 
to either UAE or hysterectomy [63]. Patient satisfaction rates and quality of life 




reported a 69% success rate with UAE while 31% of UAE treated patients experi-
enced refractory or relapsing symptoms requiring definitive treatment by hyster-
ectomy. Of note was the observation that women with BMI >25 and a history of 
smoking at baseline were more likely to require reintervention following UAE. The 
reported 69% clinical success rate is notably lower than other reported rates rang-
ing 80–90% [31]. The authors attributed the lower UAE success rate to the fact 
that eligible candidates recruited to the study suffered severe bleeding symptoms, 
and the trial required a much longer 10-year follow-up window that is only used in 
tracking outcomes [64].
The REST trial grouped women treated with myomectomy with women treated 
with hysterectomy in order to expand the UAE comparison to surgical intervention 
[65]. Women treated with either UAE or surgery enjoyed similar satisfaction rates 
and quality of life improvements at 5 years. Differences in reintervention rates were 
noted, however, as 32% of women treated with UAE required further intervention 
within 5 years as compared to 4% of women in the surgery group. A study directly 
comparing UAE to myomectomy found symptom improvement in 88.3% of UAE 
women compared to 75.4% in myomectomy at 2 years post-intervention [66]. 
Bearing the risks of reintervention in mind, the above trials affirm UAE as a safe 
procedure that enjoys rates of satisfaction and symptom improvement similar to 
those observed in hysterectomy and myomectomy. A Cochrane review of published 
RCTs comparing UAE to surgical interventions reaffirms this view and shows that 
UAE is associated with shorter hospital stays, less disability, and similar satisfaction 
rates when compared to surgical intervention [26].
10. New generation of devices
Magnetic resonance-guided high intensity focused ultrasound (MR-g HIFU) 
is a non-invasive intervention that works to thermally ablate UF via the delivery 
focused ultrasound waves [67]. Rounds of sonification and heating lasting 30 sec-
onds are interleaved with 90-second cooling-off periods; the target tissue tempera-
tures reach 60–85°C, thereby provoking coagulative necrosis of the targeted mass 
[68]. FDA guidelines regarding MR-g HIFU limit the total and percent volumes of 
uterine mass subject to thermal ablation to confine the sonification to the fibroid. 
Prospective studies tracking symptom severity scores and quality of life indices in 
women, whose UF were treated with MR-g HIFU, found significant improvement 
of both measures after at least 2 years of follow-up [67, 68]. In a direct comparison 
with UAE, however, women who underwent MR-g HIFU reported smaller improve-
ments to quality of life scores after treatment [69]. MR-g HIFU also fared worse 
in terms of reintervention rates, with women undergoing UAE experiencing a 
6.7% reintervention rate compared to a 30% reintervention rate in the MR-g HIFU 
group at mid-term follow up [69]. Potential explanations for the different outcomes 
are that MR-g HIFU treats only a single mass whereas UAE targets all masses in 
the uterus, and that MR-g HIFU ablates only a fraction of the total mass volume 
whereas UAE completely infarcts UF.
11. Conclusion
As the rates of hysterectomy fall and patient desire for less invasive management 
of uterine fibroid rises, uterine artery embolization has become increasingly promi-
nent. Two decades of experience have validated the procedure as safe and effective 
with continued advancement in procedural techniques, equipment and imaging, 
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is a non-invasive intervention that works to thermally ablate UF via the delivery 
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[68]. FDA guidelines regarding MR-g HIFU limit the total and percent volumes of 
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of both measures after at least 2 years of follow-up [67, 68]. In a direct comparison 
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6.7% reintervention rate compared to a 30% reintervention rate in the MR-g HIFU 
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are that MR-g HIFU treats only a single mass whereas UAE targets all masses in 
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As the rates of hysterectomy fall and patient desire for less invasive management 
of uterine fibroid rises, uterine artery embolization has become increasingly promi-
nent. Two decades of experience have validated the procedure as safe and effective 
with continued advancement in procedural techniques, equipment and imaging, 
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embolic agents, pain management, and operator experience lending to improved 
outcomes. There remain outstanding questions regarding UAE. Well-controlled 
investigations of fertility outcomes in women undergoing UAE or surgery for UF 
are needed. As new embolic agents become available, comparison trials to gauge 
efficacy and safety among the different agents are necessary. Continued delineation 
of patient anatomy that suggest susceptibility to ovarian insufficiency post-UAE 
is also important to ensure patients are well-counseled regarding their risks. The 
potential for further advancement leaves UAE well-positioned to continue its 
expansion in clinical practice.
Abbreviations
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MR-g HIFU magnetic resonance-guided high intensity focused ultrasound
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nsPVA non-spherical polyvinyl alcohol
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SPRM selective progesterone receptor modulators
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TAGM tris-acryl gelatin microspheres
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Leiomyoma
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Leiomyoma of the uterus is a benign tumor of the smooth muscle. It is the most 
common pathologic abnormality of the female genital tract. It is found in 20–50% 
of women older than 30 years but is rare in children and post-menopausal women. 
It can present as an asymptomatic pelvic mass or as abnormal vaginal bleeding, 
or it may be associated with painful urinary symptoms, sexual dysfunction and 
dyspareunia, infertility, and recurrent pregnancy loss. The etiology of uterine fibroids 
is unclear. Diagnosis by clinical history and physical examination, pelvic examination, 
ultrasound pelvis and CT scan, and MRI are helpful. Management can be medical 
hormonal or non-hormonal, open surgical, endoscopic, or uterine artery embolization.
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